Sanoski C A, Schoen M D, Gonzalez R C, Avitall B, Bauman J L
St. John's University College of Pharmacy and Allied Health Professions, Jamaica, New York, USA.
Pharmacotherapy. 1998 Nov-Dec;18(6 Pt 2):146S-151S.
To review the rationale and development of a multidisciplinary amiodarone clinic, and document the clinical outcomes resulting from its implementation.
A clinic was established to provide an ambulatory setting in which patients receiving amiodarone could be followed according to published guidelines by a multidisciplinary team of cardiovascular health care specialists. Patients receiving amiodarone were referred to the clinic by their primary physicians. A data base containing each patient's medical history, current drug therapy, and baseline laboratory values was developed during the initial visit. Liver function tests, thyroid function tests, and chest radiographs were performed every 6 months, and pulmonary function tests were scheduled on an annual basis. Dosage adjustments were performed in select patients.
Since November 1996, 60 patients have been referred to the amiodarone clinic. Mean length of follow-up before and after referral was 16.3+/-25.5 and 9.2+/-5.5 months, respectively. Laboratory tests were performed according to accepted guidelines in 14 (23%) patients before referral compared with 54 (90%) patients after enrollment (p<0.001). Previously unrecognized adverse events were detected in 21 (35%) patients, including pulmonary fibrosis, QT prolongation, liver enzyme elevation, hypothyroidism, hyperthyroidism, and asthma exacerbation. Amiodarone was discontinued in six patients, four of whom had suspected pulmonary toxicity. The dose of amiodarone was adjusted in 29 (48.4%) patients.
Many patients receiving amiodarone are not being followed according to published recommendations. Implementation of a specialized, multidisciplinary amiodarone clinic improves outcomes by monitoring for early detection of drug-related toxicities and by facilitating proper dosage modifications.
回顾多学科胺碘酮门诊的设立依据及发展情况,并记录其实施后的临床结果。
设立一个门诊,为接受胺碘酮治疗的患者提供一个门诊环境,由心血管保健专家多学科团队按照已发表的指南对其进行随访。接受胺碘酮治疗的患者由其初级医生转诊至该门诊。在初次就诊时建立一个包含每位患者病史、当前药物治疗及基线实验室值的数据库。每6个月进行肝功能检查、甲状腺功能检查及胸部X线检查,每年安排肺功能检查。对部分患者进行剂量调整。
自1996年11月以来,已有60例患者被转诊至胺碘酮门诊。转诊前后的平均随访时间分别为16.3±25.5个月和9.2±5.5个月。转诊前14例(23%)患者按照公认指南进行了实验室检查,而登记后有54例(90%)患者进行了检查(p<0.001)。在21例(35%)患者中检测到先前未被识别的不良事件,包括肺纤维化、QT间期延长、肝酶升高、甲状腺功能减退、甲状腺功能亢进及哮喘加重。6例患者停用了胺碘酮,其中4例怀疑有肺毒性。29例(48.4%)患者调整了胺碘酮剂量。
许多接受胺碘酮治疗的患者未按照已发表的建议进行随访。设立专门的多学科胺碘酮门诊,通过监测以早期发现药物相关毒性并促进适当的剂量调整,可改善治疗结果。